Reflexion Medical, partially based on research at UChicago, secured the Rise Fund as lead investor, with Pfizer and Johnson & Johnson returning.
US-based medical equipment manufacturer Reflexion Medical secured $100m in a series C round yesterday that featured the respective corporate venturing units of pharmaceutical firms Pfizer and Johnson & Johnson.
Pfizer Venture Investments and Johnson & Johnson Innovation – JJDC invested alongside the Rise Fund, an impact investment fund managed by TPG Growth, which led the round.
T. Rowe Price, GT Healthcare Capital Partners, Sofinnova Partners, KCK Group and Venrock also participated in the series C round.
Reflexion Medical is working on biology-guided, personalised radiotherapy technology that identifies and tracks tumours in real time, allowing for higher doses of radiation aimed precisely at lesions without danger of damaging surrounding, healthy tissue.
The technology is partially based on research undertaken at University of Chicago, from which it was licensed in 2011.
Reflexion previously closed a $52m series B round in July 2016 after Johnson & Johnson Innovation – JJDC supplied a $6m extension. Pfizer Venture Investments had supported a $46m first tranche in April 2016 led by KCK, with participation from Sofinnova and Venrock.
Pfizer Venture Investments had already backed an $11.6m series A round in 2014 alongside Venrock and lead investor Sofinnova.
– This article first appeared on our sister site, Global Corporate Venturing.
